Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Xenon Pharmaceuticals Inc. XENE

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
21.97
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 1 1 1 — 6 — — 2 — 2 —
Insider Ownership
7.84%

Capital & Financial Ratios

Market Cap
4,060.00
Revenue
16.93
Net Income
(409.19)
Free Cash Flow
(338.53)
Net Debt
(930.69)
Current Ratio
21.02
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
233.82
P/B ratio
3.19
Past 5Y EPS Growth
(14.28%)
This Y EPS Growth
(5.71%)
Next Y EPS Growth
(2.90%)
Next 5Y EPS Growth
7.27%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 638.08 626.91 548.89 930.69
Receivables 0.87 1.47 1.37 1.63
Inventory — — — —
Other — — — —
644.96 635.26 560.65 945.87
2023 2024 2025 Q'26
Payables 25.97 34.22 40.26 43.67
ST’ Debt — — — —
Other — — — —
27.27 35.59 41.79 45.01
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’25 7.50 — — —
7.50
’22 8.77 0.54 0.13 —
9.43
’21 4.36 2.22 8.12 3.74
18.44
’20 7.08 13.38 6.55 5.15
32.17
’19 — — 3.50 3.33
6.83
’17 0.02 0.02 0.26 0.02
0.31
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (88.90) (95.39) — —
—
’25 (61.65) (64.23) (71.75) (81.48)
(279.12)
’24 (46.19) (31.15) (49.66) (54.38)
(181.39)
’23 (34.41) (33.22) (48.08) (35.40)
(151.11)
’22 (18.43) (16.87) (30.40) (32.73)
(98.43)
’21 (20.71) (13.08) (15.01) (20.71)
(69.50)
’20 (13.07) (10.79) (11.15) (13.11)
(48.12)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (89.03) (95.66) — —
—
’25 (61.69) (64.39) (72.03) (81.80)
(279.92)
’24 (46.37) (32.67) (50.25) (55.17)
(184.46)
’23 (36.62) (35.35) (49.28) (35.48)
(156.73)
’22 (18.64) (17.41) (30.79) (34.48)
(101.32)
’21 (21.11) (13.99) (15.23) (21.22)
(71.55)
’20 (13.71) (11.16) (11.95) (13.94)
(50.76)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (1.17) (1.11) — —
—
’25 (0.83) (1.07) (1.15) (1.31)
(4.36)
’24 (0.62) (0.75) (0.81) (0.84)
(3.01)
’23 (0.63) (0.72) (0.73) (0.64)
(2.73)
’22 (0.35) (0.55) (0.57) (0.57)
(2.06)
’21 (0.42) (0.51) (0.36) (0.57)
(1.77)
’20 (0.22) 0.00 (0.25) (0.34)
(0.81)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.2
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡‡ 24.60 27.99 35.53 26.74 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 41.39 47.00 50.99 46.60 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 213 259 327 370 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.04 0.00 0.00 0.02 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.43 — — 7.50 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% — — 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (125.25) (182.68) (238.42) (344.89) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,327.70%) 0.00% 0.00% (4,598.59%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (125.37) (182.39) (234.33) (345.91) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.62 2.06 2.56 2.54 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.16 0.00 0.00 0.09 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.06) (2.73) (3.01) (4.36) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.63) (2.26) (2.33) (3.52) ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.05) (0.08) (0.04) (0.01) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.67) (2.34) (2.37) (3.53) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.92 13.87 9.69 7.34 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 60.54 66.89 77.89 79.25 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ — ‡‡‡ ‡‡‡ ‡‡‡ 0.00 — — 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 171.27 — — 209.76 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.13 — — 6.11 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 127.11 — — 178.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.52) — — (10.77) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (98.43) (151.11) (181.39) (279.12) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.89) (5.62) (3.07) (0.80) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (101.32) (156.73) (184.46) (279.92) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 577.60 617.69 599.67 518.86 — — —
Working Cap'
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.44 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (581.65) (638.08) (626.90) (548.89) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 721.50 927.92 754.90 581.76 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (18.84%) (21.22%) (26.58%) (48.34%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (57.72%) (46.16%) (136.38%) (709.28%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (19.77%) (22.12%) (27.85%) (51.76%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Xenon Pharmaceuticals (XENE), a clinical-stage biotech powerhouse targeting epilepsy and sleep disorders, rides the biotech rollercoaster with its star candidate XEN1101 delivering blockbuster Phase 2b results that once ignited a share surge. Despite mounting losses—ballooning to $234 million in 2024 amid zero recent revenue and a 248% employee headcount explosion—the company boasts a fortress balance sheet with $627 million in net cash, providing ample runway for Phase 3 trials without immediate dilution fears.

Stock volatility mirrors pipeline hype, with shares up over 500% since 2016 despite dilution and negative fundamentals, trading at sky-high multiples on trial momentum. Insider caution flags emerge: CEO-led sells totaling $3.9 million and zero buys, contrasting analyst optimism for 33% average upside to targets amid deeply negative forward P/E.

Looking ahead, revenue is forecasted to explode from zero to $74 million by 2027 on potential XEN1101 approvals and partnerships, though losses deepen further short-term. For retail investors, it’s a high-stakes bet on neurology breakthroughs versus trial risks and competition—position small, watch Phase 3 data closely, and brace for 50% swings in this classic speculative biotech tale.

Read full commentary →

Xenon Pharmaceuticals Inc. (XENE) Latest News

News by impact score

Fine-tune

19 Sep

4 , 8:20 PM
Xenon Pharmaceuticals paused psychiatry trials, triggering a 32.2% stock drop despite positive NDA data. Pausing psychiatry trials disrupts Xenon Pharmaceuticals' core pipeline and drives major stock decline.

18 Sep

5 , 11:12 AM
Xenon Pharmaceuticals stock fell 30% after a drug trial setback. The failure may benefit a competing biotech company. Drug trial failure triggered 30% stock drop and signals major pipeline setback for Xenon.

4 www.barchart.com, 3:00 PM
Xenon Pharmaceuticals paused a drug trial, triggering a sharp drop in XENE stock. Drug trial pause directly disrupts pipeline progress and triggers major investor sell-off.

4 www.proactiveinvestors.com, 11:27 AM
Xenon Pharmaceuticals stock plunged 30% after pausing enrollment in its depression trial. Depression trial pause directly endangers core pipeline progress and triggers sharp investor selloff.

4 , 11:09 AM
Xenon Pharmaceuticals filed an NDA for its epilepsy drug but stock declined following setbacks in depression studies. NDA filing advances core epilepsy program toward potential approval while depression study setbacks introduce pipeline risk and immediate share pressure.

4 , 8:48 AM
Xenon Pharmaceuticals stock sharply declined after a drug trial setback, with the failure potentially benefiting a rival company. Drug trial failure directly threatens Xenon's core pipeline, valuation and competitive position.

4 www.biopharmadive.com, 7:51 AM
Xenon Pharmaceuticals shares declined after the company paused its depression trial. Depression trial pause directly disrupts pipeline progress and reduces investor confidence.

3 , 11:21 AM
RBC Capital Markets states that Xenon Pharmaceuticals' Azetukalner retains its core value in epilepsy treatment. Analyst note reaffirms Azetukalner's established role without signaling new developments or major shifts.

3 , 6:54 AM
Xenon Pharmaceuticals paused enrollment in depression studies, triggering a fall in its shares. Pausing enrollment in depression studies introduces delays to core clinical programs and pressures near-term stock performance.

17 Sep

5 , 4:01 PM
Xenon Pharmaceuticals submitted an NDA to the FDA for azetukalner in focal seizures and updated its psychiatry clinical program. NDA submission for azetukalner marks pivotal regulatory milestone that could redefine company trajectory upon approval.

10 Sep

4 , 9:36 AM
Biohaven shares plunged after a surprise setback in its seizure drug program, handing a competitive edge to rival Xenon Pharmaceuticals. Biohaven clinical failure directly strengthens Xenon's position in the seizure-treatment market.

4 Sep

4 , 3:06 PM
Xenon Pharmaceuticals advances into Europe with clinical data that may transform epilepsy treatment standards. European expansion with high-impact epilepsy data signals major strategic growth and market gains ahead.

28 Aug

4 , 4:20 AM
Xenon Pharmaceuticals released new Phase 3 data for azetukalner in epilepsy, with results carrying direct implications for shareholder value and the company's positioning in neurological drug development. Phase 3 epilepsy data for lead candidate azetukalner can substantially shift XENE's trajectory, investor sentiment, and competitive standing in biotech.

26 Aug

4 , 4:01 PM
Xenon Pharmaceuticals will highlight Phase 3 X-TOLE2 clinical data and azetukalner rational polytherapy potential at EEC 2026. Phase 3 data presentation at major epilepsy conference signals major pipeline progress with direct effect on valuation and approval prospects.

13 Aug

3 transcript www.fool.com, 5:58 PM
Xenon Pharmaceuticals Inc. released its Q2 2026 earnings call transcript covering quarterly financial results, pipeline progress, and management commentary on operations and outlook. Earnings call delivers standard quarterly updates on finances and development programs that may sway short-term sentiment without indicating major strategic shifts.

7 Aug

4 , 2:02 PM
Xenon Pharmaceuticals maintains Azetukalner NDA filing timeline after FDA meeting per RBC analysis. Azetukalner NDA progress marks major regulatory milestone advancing Xenon pipeline toward potential approval.

4 transcript , 1:09 AM
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 earnings call highlighted progress advancing azetukalner through clinical development stages. Progress on azetukalner directly drives pipeline value and future revenue potential for Xenon.

3 transcript www.marketbeat.com, 4:04 PM
Xenon Pharmaceuticals Inc. released Q2 earnings call highlights covering financial results, pipeline progress and operational updates for the period. Q2 earnings call highlights deliver financial and pipeline updates that can shift near-term investor sentiment without altering long-term company trajectory.

6 Aug

3 , 4:01 PM
Xenon Pharmaceuticals Inc. (XENE) reported its Q2 2026 financial results and issued a business update. Quarterly earnings releases with business updates deliver performance data that can shift near-term sentiment without fundamentally changing long-term trajectory.

18 May

3 www.fool.com, 1:44 PM
A fund acquired $22 million in Xenon Pharmaceuticals (XENE) shares ahead of an FDA filing. Fund purchase ahead of FDA filing may lift near-term sentiment without altering long-term trajectory.

11 May

5 Simply Wall St., 11:13 AM
Xenon Pharmaceuticals (XENE) valuation reassessed following successful Phase 3 X-TOLE2 trial results for epilepsy treatment and extended cash runway to 2027, highlighting improved financial stability and path to regulatory submission. Phase 3 X-TOLE2 success paves way for regulatory approval of key epilepsy drug, profoundly boosting XENE's pipeline value and long-term prospects.

4 Simply Wall St., 4:13 AM
Xenon Pharmaceuticals (XENE) reports positive X-TOLE2 trial data and completes a major cash raise, potentially shifting its investment narrative toward stronger growth prospects. Positive X-TOLE2 data advances clinical pipeline while major cash raise extends runway, significantly boosting valuation and investor sentiment.

9 May

4 www.marketbeat.com, 4:07 AM
Xenon Pharmaceuticals Q1 earnings call highlights financial results, clinical pipeline updates, and forward guidance. Q1 earnings highlights detail financial performance and pipeline progress that could significantly impact stock trajectory and investor sentiment.

8 May

3 Zacks, 12:47 PM
Xenon Pharmaceuticals Inc. (XENE) Q1 earnings matched analyst estimates, spotlighting pipeline development. Q1 earnings met expectations with pipeline emphasis, moderately influencing financial stability and future growth prospects.

7 May

4 transcript www.fool.com, 6:20 PM
Xenon Pharmaceuticals Inc. (XENE) released Q1 2026 earnings call transcript covering financial results, pipeline updates, and forward guidance. Q1 2026 earnings transcript details financial performance, clinical trial progress, and strategic outlook with potential to drive significant stock volatility and investor reassessment.

3 GlobeNewswire, 4:01 PM
Xenon Pharmaceuticals Inc. (XENE) reported Q1 2026 financial results and provided a business update. Quarterly financial results and business update moderately influence financial performance and investor sentiment.

26 Apr

4 www.marketbeat.com, 1:05 AM
Xenon Pharmaceuticals presented strong Phase III data for azetukalner and announced Q3 NDA filing plans at the Bloom Burton Conference. Strong Phase III data and imminent Q3 NDA submission for azetukalner signal a major regulatory milestone that could drive substantial stock gains and reshape Xenon's pipeline value.

23 Apr

4 Insider Monkey, 5:47 AM
Xenon Pharmaceuticals Inc. (XENE) eyes a $2 billion opportunity in its pipeline developments. $2 billion opportunity signals major strategic potential to elevate XENE's competitive position and investor sentiment.

19 Apr

5 , 6:00 PM
Xenon Pharmaceuticals presented azetukalner Phase 3 X-TOLE2 study results and 48-month long-term data demonstrating efficacy in focal onset seizures at the 2026 AAN Annual Meeting. Phase 3 results and long-term data for azetukalner position Xenon for potential FDA approval in epilepsy, transforming its pipeline and market prospects.

7 Apr

4 GlobeNewswire, 8:30 AM
Xenon Pharmaceuticals will present Phase 3 X-TOLE2 trial and long-term data for azetukalner in focal onset seizures at the 2026 AAN Annual Meeting. Highlighting Phase 3 data and long-term results for azetukalner at AAN represents a major milestone that could significantly influence regulatory progress and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us